Eloxx Pharmaceuticals, Inc.·4

May 8, 4:44 PM ET

Walts Alan Edmund 4

4 · Eloxx Pharmaceuticals, Inc. · Filed May 8, 2026

Research Summary

AI-generated summary of this filing

Updated

Eloxx (ELOX) Director Alan Walts Receives RSUs and Exercises Options

What Happened

  • Alan Edmund Walts, a director of Eloxx Pharmaceuticals (ELOX), was granted 395,680 restricted stock units (RSUs) on Sept 19, 2025 (reported at $0). The Form 4 also shows activity on Jan 24, 2026 in which 1,875 derivative shares were converted/exercised and a matching 1,875 shares were reported as disposed; both the acquisition/disposition entries are reported with $0 (one acquisition line shows price as N/A).
  • The RSU grant is an award (no cash purchase). The Jan 24, 2026 activity reflects conversion/exercise of derivative securities and a same-day disposition of the resulting shares (reported values $0 / N/A in the filing).

Key Details

  • Transaction dates and reported amounts:
    • 2025-09-19: Grant/award (A) — 395,680 RSUs @ $0.00 (derivative award).
    • 2026-01-24: Exercise/conversion (M) — 1,875 shares acquired (price N/A) and 1,875 shares disposed @ $0.00.
  • Shares owned after the transactions: Not specified in the provided data (not reported here).
  • Relevant footnotes from the filing:
    • F1: Each RSU represents a contingent right to receive one share of common stock.
    • F2: The stock option vests 1/36 on Oct 31, 2025, then monthly over 35 months, subject to continuous service.
    • F3: The RSUs vested 50% on the first anniversary of Jan 24, 2024, with the remainder vesting in two equal annual installments.
  • Timeliness: The Form 4 was filed May 8, 2026 for activity dated Sept 19, 2025 and Jan 24, 2026 — this appears to be a late filing relative to the typical 2-business-day Form 4 deadline.

Context

  • RSU grants (award A) are compensation and do not imply an outlay by the insider; they are commonly used for pay/retention. The filing shows both an exercise/conversion and a same-day disposition of 1,875 derivative shares — the filing reports $0/N/A amounts and does not explain the reason for the disposition (e.g., transfer, tax withholding, or other plan mechanics).
  • For retail investors, grants and vesting schedules are useful to track potential future share issuance; same-day exercise/disposal activity can reflect routine plan settlements rather than a directional investment bet.

Insider Transaction Report

Form 4
Period: 2025-09-19
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-01-24+1,87515,567 total
  • Award

    Stock Option (Right to Buy)

    [F2]
    2025-09-19+395,680395,680 total
    Exercise: $0.15Exp: 2035-09-19Common Stock (395,680 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F3]
    2026-01-241,8751,875 total
    Common Stock (1,875 underlying)
Footnotes (3)
  • [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
  • [F2]The stock option vested as to 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.
  • [F3]The RSUs vested as to 50% on the first anniversary of January 24, 2024, and the remaining amount vested in two equal annual installments thereafter.
Signature
/s/ Sumit Aggarwal, Attorney-in-Fact|2026-05-08

Documents

1 file
  • 4
    ownership.xmlPrimary

    4